DISCOVER: More Favorable Renal and Bone Outcomes With FTC/TAF vs FTC/TDF for HIV PrEP Through 96 Wks

March 8-11, 2020; Boston, Massachusetts
Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: March 15, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Short video log from Jürgen Rockstroh, MD, on treating an older man recently diagnosed with HIV/HBV coinfection

Jürgen K. Rockstroh, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 20, 2020 Expired: October 19, 2021

Expert-authored CCO slides on strategies encompassed by the Ending the HIV Epidemic Initiative, including prevention and rapid diagnosis and treatment

W. David Hardy, MD
Program Director
David A. Wohl, MD
Released: October 20, 2020

Expert-authored CCO slides on simplification to 2-drug ART, ART safety during pregnancy, ART and weight gain, and long-acting injectable ART

W. David Hardy, MD
Program Director
Michelle S. Cespedes, MD, MS
Released: October 20, 2020

Download free expert-authored slides reviewing a patient case and the relevant data and guidance on HIV/HBV coinfection in older patients

Jürgen K. Rockstroh, MD Released: October 20, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue